Check out Entire Prescribing Info OPDIVO® (nivolumab) is indicated for that treatment of Grownup patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed immediately after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or after 3 or ev